Clearside Biomedical

Clearside Biomedical ROCE

Delisted

The Return on Capital Employed (ROCE) of Clearside Biomedical (CLSD) as of Nov 20, 2026 is 74.33 %. In the previous year, Return on Capital Employed (ROCE) was 156.13 % — a change of -52.39% (lower).

ROCE

74.33 %

YoY

-52.39%

Last updated:

In 2024, Clearside Biomedical's return on capital employed (ROCE) was 74.33 %, a -52.39% increase from the 156.13 % ROCE in the previous year.

The Clearside Biomedical ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-272.82 USD
Jan 1, 2018
-351.19 USD
Jan 1, 2019
-271.51 USD
Jan 1, 2020
-204.79 USD
Jan 1, 2021
-1.63 USD
Jan 1, 2022
-285.66 USD
Jan 1, 2023
156.13 USD
Jan 1, 2024
74.33 USD
The Clearside Biomedical ROCE history
YEARROCEYoY
74.33 %-52.39%
156.13 %-154.66%
-285.66 %+17,394.39%
-1.63 %-99.20%
-204.79 %-24.57%
-271.51 %-22.69%
-351.19 %+28.73%
-272.82 %+675.79%
-35.17 %-78.36%
-162.48 %+26.08%
-128.87 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Clearside Biomedical's Return on Capital Employed (ROCE)

Clearside Biomedical's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Clearside Biomedical's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Clearside Biomedical's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Clearside Biomedical’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Clearside Biomedical stock

Return on Capital Employed (ROCE) of Clearside Biomedical is 74.33 % in 2024.

Return on Capital Employed (ROCE) of Clearside Biomedical changed from 156.13 % to 74.33 %, representing a -52.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Clearside Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Clearside Biomedical

All Key Metrics — Clearside Biomedical